Amgen (NASDAQ: AMGN) shares fell approximately 10% to $394.38 by midday Tuesday September 8, 2026 as investors continued to reprice the entire Lp(a)-lowering cardiovascular hypothesis following Novartis' Friday September 4 announcement that pelacarsen missed the primary MACE endpoint in the Phase 3 Lp(a)HORIZON trial. Amgen's olpasiran (RNAi Lp(a) suppressor) is the most direct readthrough: the Phase 3 OCEAN(a) trial is enrolling patients with elevated Lp(a) and established cardiovascular disease with a similar Lp(a)-lowering-plus-cardiovascular-outcome design and is estimated to read out 2027-2028. Lilly's lepodisiran (RNAi) is running in a broader group including primary-prevention patients, which analyst commentary suggests partly insulates it from the Novartis-specific readthrough. Silence Therapeutics' zerlasiran (RNAi) lowered Lp(a) by up to 85% at 36 weeks in ALPACAR-360; Silence has FDA feedback on a proposed Phase 3 design but is dependent on securing a development partner. The Lp(a) hypothesis question is now whether the drug class lowers hard cardiovascular outcomes, not whether the class lowers Lp(a) levels — that latter question was already answered in the affirmative.
Novo Nordisk (NYSE: NVO) announced at ESC Congress 2026 that its Phase 3 ZEUS trial of ziltivekimab (an anti-IL-6 monoclonal antibody in development for cardiovascular risk reduction in inflammation-driven disease) failed to reduce major adverse cardiovascular events (MACE) versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP ≥2 mg/L). The three-component MACE primary endpoint hazard ratio was 0.99 (95% CI 0.88-1.11), despite confirmed IL-6 pathway engagement (reductions in free IL-6 and hsCRP as expected). Safety was broadly similar between arms though serious infections were more frequent on ziltivekimab (consistent with the IL-6 class). NVO shares fell more than 9% on the readout, deepening the widening H1 2026 GLP-1 revenue gap that already sat at $10.2 billion versus Eli Lilly. Novo has committed to continuing the two other cardiovascular outcomes trials (HERMES in heart failure, ARTEMIS post-acute MI) with H1 2027 readouts. The ZEUS miss casts doubt on the broader thesis of anti-inflammatory cardiovascular risk reduction via IL-6 blockade.
Novartis (NYSE: NVS) reiterated at ESC Congress 2026 Saturday August 29 that it will advance the Phase 3 program for pacibekitug (an anti-IL-6 monoclonal antibody acquired from Tourmaline Bio through the $1.4 billion acquisition completed earlier in 2026) for cardiovascular risk reduction in inflammation-driven disease, notwithstanding the Phase 3 ZEUS trial failure of Novo Nordisk's ziltivekimab announced the same weekend. Novartis's stance is that ZEUS was underpowered in the specific ASCVD-plus-CKD-plus-inflammation subgroup rather than a class-level miss for IL-6 blockade, and that pacibekitug's differentiated pharmacokinetic profile (longer half-life and less frequent dosing) plus the differently-selected patient population in the planned Phase 3 will allow the mechanism to prove out. The commitment is a $1.4 billion acquisition-scale bet against the base-rate signal from ZEUS and continues the pattern of large pharma anti-inflammatory cardiovascular pipeline commitment following the earlier successful CANTOS canakinumab (IL-1β) proof of concept.
Wiley's Diabetes, Obesity and Metabolism published in August 2026 pooled subgroup analyses from Novo Nordisk's Phase 3 SOUL (oral semaglutide 14 mg in type 2 diabetes with ASCVD/CKD) and SELECT (semaglutide 2.4 mg in overweight/obesity with established cardiovascular disease) trials examining whether cardiovascular benefit of semaglutide varies by baseline aspirin use. Analyses (Müller-Wieland et al.) concluded that semaglutide significantly reduces major adverse cardiovascular events irrespective of baseline aspirin therapy in individuals with T2DM or overweight/obesity without diabetes at high cardiovascular risk. The pooled MACE benefit is directionally consistent in aspirin users and non-users. Clinical implication: cardiovascular protection from semaglutide is additive to baseline antiplatelet therapy and does not require aspirin discontinuation, addressing a long-standing question about interaction between the GLP-1 receptor agonist class and standard secondary-prevention regimens in older cardiovascular patients.
AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before market open Monday July 27, 2026 with core earnings per share of $2.63 for the three months ended June 30 (+18% constant currency), beating consensus of $2.48. Revenue of $15.38 billion was in line with consensus of $15.39 billion (+5%). Analyst focus on the earnings call centered on the pipeline update: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE (positive data at ADA 2026 Scientific Sessions in June), has moved into a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved April 2026). AstraZeneca separately revised the peak sales projection for tozorakimab (experimental respiratory treatment) to above $5 billion from the previous $3 billion estimate. AZN shares rose approximately 1.7% in London Monday morning trading.
Analyst coverage of Merck's LIPFENDRA (enlicitide) FDA approval (Thursday July 16) crystallized Friday. Financial analysts projected LIPFENDRA can generate more than $2 billion in annual sales after a few years on the market. RBC Capital Markets described the label as 'the cleanest in the PCSK9 class,' noting zero contraindications or hypersensitivity warnings, unlike the currently approved injectable PCSK9 competitors (Amgen Repatha/evolocumab, Regeneron/Sanofi Praluent/alirocumab, and Novartis Leqvio/inclisiran). In supporting Phase 3 data, LIPFENDRA statistically outperformed other oral non-statin drugs (Nexletol/bempedoic acid and Zetia/ezetimibe) in adjunctive hypercholesterolemia populations. LIPFENDRA continues to be evaluated in the large cardiovascular outcomes trial CORALreef Outcomes (NCT06008756), which Merck confirmed has completed enrollment with more than 14,500 participants. It is not yet known whether LIPFENDRA reduces cardiovascular morbidity and mortality; the outcomes trial will address that question. Additional data on the safety profile: in CORALreef Lipids, adverse-reaction frequencies were similar between LIPFENDRA and placebo; in CORALreef HeFH the most common adverse reactions more frequent versus placebo were diarrhea (7% vs. 2%) and dizziness (9% vs. 4%), with discontinuation rates similar to placebo.
Novo Nordisk US Operations EVP Jamey Millar released a formal statement Wednesday July 1, 2026, framing the Medicare GLP-1 Bridge as 'an important step in getting Wegovy to more patients' and committing to continued work with CMS, healthcare professionals, pharmacists, and patient advocates on Bridge implementation. Millar's cardiovascular-outcome framing was the piece of the statement designed to distinguish Wegovy from competitor GLP-1s under the Bridge: 'Obesity is a serious, common chronic disease facing older Americans, and Wegovy is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions.' The SELECT trial data (2023-2024) underpin the cardiovascular claim. The Bridge covers all doses and formulations of Wegovy injection (including the 7.2 mg Wegovy HD launched April 2026) and Wegovy pill (1.5, 4, 9, and 25 mg oral tablets, launched January 5, 2026 and reaching 3 million prescriptions by June 7). The program is available nationwide across all US states and territories through December 31, 2027. PharmExec and PR Newswire ran the announcement.